Riskpilot← Back to searchSign inGet full accessCollagenum AB
ABDissolvedOrg 5591502843VästervikResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
SEK 1K
-96% vs 2023
EBITDA margin
-400.0%
-124% vs 2023
Equity ratio
83.0%
Financial strength
Net profit 2024
SEK 0
-100% vs 2023
| Revenue | SEK 1K | -96% |
| EBITDA | SEK -4K | -124% |
| Net profit | SEK 0 | -100% |
| Total assets | SEK 141K | -9% |
| Equity | SEK 117K | +0% |
| Employees | 0 | — |
Legal name
Collagenum AB
Org number
5591502843
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23 februari 2018
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva utveckling, tillverkning och försäljning av produkter inom biomedicinsk forskning, samt för att främja vård och hälsa hos såväl djur som människor. Bolaget ska även utföra tjänster inom forskning och utveckling samt därmed förenlig verksamhet.
Address
Västervik
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 28 | 40 | 28 | 1 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −10 | — | 31 | 17 | −4 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −10 | 0 | 31 | 17 | −4 |
| Net financials | — | — | — | — | — |
| Profit before tax | −10 | 0 | 31 | 13 | 0 |
| Tax | −0 | −0 | −2 | −3 | −0 |
| Net profit | −10 | 0 | 29 | 10 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 97 | 99 | 132 | 155 | 141 |
| Equity | 78 | 77 | 106 | 117 | 117 |
| Long-term debt | 19 | 20 | 21 | 21 | 22 |
| Short-term debt | 0 | 2 | 5 | 13 | 3 |
| Total debt | 19 | 22 | 26 | 34 | 25 |
EBITDA margin
-400.0%
This company
15.8%
Market median
-2632% vs market
20202024
Equity ratio
83.0%
This company
38.2%
Market median
+117% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Former (3) | ||
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Chairman | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Collagenum AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alexandra Palaemona Bäcklund | Board of Directors | 0 companies |
| Gunilla Maria Krüger | Deputy Board Member | 0 companies |
| Per Lennart Anderzon | Board of Directors | 0 companies |
| Karl Johan Bäcklund | Chairman | 0 companies |
| Anders Johan Krüger | Board of Directors | 0 companies |